Odyssey Therapeutics

Odyssey Therapeutics, Inc. operates as a biotechnology company focused on developing next-generation precision immunomodulators and oncology medicines. The firm was founded in 2021 by Gary D. Glick, Ph.D., a serial biotech entrepreneur with a background in chemistry and a track record of founding successful companies like Lycera, IFM Therapeutics, and Scorpion Therapeutics. Glick's journey began as a chemistry professor at the University of Michigan before he transitioned into the biotech industry, driven by a problem-first approach to drug discovery rather than focusing on a specific technology.

The company's business is centered on creating a sustainable pipeline of therapeutics for cancer and inflammatory diseases affecting large patient populations. Odyssey has established a highly integrated drug discovery engine that combines advanced computational tools, including artificial intelligence and machine learning, with deep expertise in chemistry and biology to tackle challenging drug targets. This engine is designed to accelerate the identification and development of both small-molecule and protein-based therapies. The company's revenue model is predicated on the successful development and commercialization of its product candidates, which involves substantial investment in research and development funded by significant venture capital.

Odyssey's discovery platform is a key differentiator, integrating physics-based molecular simulations, AI, and machine learning to unlock high-value targets, some of which were previously considered undruggable. In a strategic move to bolster these capabilities, the company acquired Rahko, a quantum machine learning company, in January 2022. This acquisition integrated a platform that uses computational chemistry, machine learning, and quantum computing to better simulate drug behavior and identify novel binding sites. Odyssey's pipeline includes multiple preclinical programs in immunology and oncology. The company has raised substantial capital to advance these programs toward clinical trials, securing a $218 million Series A in December 2021, a $168 million Series B in October 2022, and a $101 million Series C in December 2023, bringing its total funding to nearly $500 million within its first few years.

Keywords: precision medicine, immunomodulators, oncology therapeutics, drug discovery engine, Gary Glick, small molecule drugs, protein therapeutics, inflammatory diseases, computational chemistry, machine learning in drug discovery, quantum machine learning, drug development, cancer research, immunology, preclinical programs, venture-backed biotech, covalent libraries, molecular glues, functional genomics, clinical development